ANI Pharma insider plans $380K stock sale

Form 144 reports Nikhil Lalwani’s planned and recent Rule 144 sales of ANI Pharmaceuticals common stock, including 5,400 shares tied to restricted stock awards.

Rhea-AI Filing Summary

ANI PHARMACEUTICALS INC (ANIP) received a notice that Nikhil Lalwani plans to sell common stock under Rule 144. The notice covers 5,400 shares of common stock, with an indicated aggregate market value of $380,160.00, against 22,959,488 shares of common stock outstanding on NASDAQ.

The shares to be sold relate to Restricted Stock Awards, with the prospective sale date shown as February 28, 2026. The filing also lists a prior Rule 10b5-1 sale of 5,400 shares of common stock on August 25, 2026 for proceeds of $401,216.22.

Key Figures

Planned shares to be sold: 5,400 shares Aggregate market value of planned sale: $380,160.00 Shares outstanding: 22,959,488 shares +3 more

6 metrics

Planned shares to be sold 5,400 shares Common stock covered by the Rule 144 notice related to Restricted Stock Awards

Aggregate market value of planned sale $380,160.00 Indicated market value for the 5,400 shares covered by the notice

Shares outstanding 22,959,488 shares Common stock outstanding referenced in connection with the NASDAQ-listed shares

Prior 10b5-1 sale shares 5,400 shares Common stock sold on August 25, 2026 under a Rule 10b5-1 sale

Proceeds from prior 10b5-1 sale $401,216.22 Value of 5,400 shares of common stock sold on August 25, 2026

Prospective sale date for planned transaction February 28, 2026 Date listed for the Restricted Stock Awards shares to be sold

Key Terms

Rule 144, Restricted Stock Awards, 10b5-1, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Awards financial

"Common | 02/28/2026 | Restricted Stock Awards | Issuer"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

10b5-1 regulatory

"10b5-1 Sales for NIKHIL LALWANI 104 Carnegie Center Drive"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for ANIP?

The filing discloses that Nikhil Lalwani intends to sell 5,400 shares of ANI Pharmaceuticals common stock under Rule 144, related to restricted stock awards, with an indicated aggregate market value of $380,160.00 and a prospective sale date of February 28, 2026.

How many shares of ANIP common stock are covered by the planned Rule 144 sale?

The planned Rule 144 sale covers 5,400 shares of ANI Pharmaceuticals common stock, associated with Restricted Stock Awards, with a prospective sale date listed as February 28, 2026.

What is the indicated market value of the ANIP shares in the planned Rule 144 sale?

The indicated aggregate market value of the 5,400 shares of ANI Pharmaceuticals common stock covered by the planned Rule 144 sale is $380,160.00, based on the information provided in the notice.

How many ANIP shares were sold in the past three months under Rule 10b5-1?

In the past three months, a Rule 10b5-1 sale for Nikhil Lalwani shows that 5,400 shares of ANI Pharmaceuticals common stock were sold on August 25, 2026 for proceeds of $401,216.22.

What is the reported number of ANIP shares outstanding in this filing?

The filing reports 22,959,488 shares of ANI Pharmaceuticals common stock outstanding, providing context for the planned sale of 5,400 shares under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:24 PM Accepted by SEC EDGAR 09/15/2026 - 04:24 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001822629
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ANI PHARMACEUTICALS, INC.
SEC File Number	001-31812
Address of Issuer	104 Carnegie Center Drive, Suite 300 Princeton NEW JERSEY 08540
Phone	(609)759-1810
Name of Person for Whose Account the Securities are To Be Sold	NIKHIL LALWANI
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5400	380160.00	22959488	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/28/2026	Restricted Stock Awards	Issuer			5400	02/28/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for NIKHIL LALWANI 104 Carnegie Center Drive, Suite 300 Princeton NJ 08540	Common	08/25/2026	5400	401216.22

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Nikhil Lalwani
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)